LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study
- PMID: 37280213
- PMCID: PMC10244395
- DOI: 10.1038/s41398-023-02490-7
LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study
Abstract
Evidences have shown that both LRFN5 and OLFM4 can regulate neural development and synaptic function. Recent genome-wide association studies on major depressive disorder (MDD) have implicated LRFN5 and OLFM4, but their expressions and roles in MDD are still completely unclear. Here, we examined serum concentrations of LRFN5 and OLFM4 in 99 drug-naive MDD patients, 90 drug-treatment MDD patients, and 81 healthy controls (HCs) using ELISA methods. The results showed that both LRFN5 and OLFM4 levels were considerably higher in MDD patients compared to HCs, and were significantly lower in drug-treatment MDD patients than in drug-naive MDD patients. However, there were no significant differences between MDD patients who received a single antidepressant and a combination of antidepressants. Pearson correlation analysis showed that they were associated with the clinical data, including Hamilton Depression Scale score, age, duration of illness, fasting blood glucose, serum lipids, and hepatic, renal, or thyroid function. Moreover, these two molecules both yielded fairly excellent diagnostic performance in diagnosing MDD. In addition, a combination of LRFN5 and OLFM4 demonstrated a better diagnostic effectiveness, with an area under curve of 0.974 in the training set and 0.975 in the testing set. Taken together, our data suggest that LRFN5 and OLFM4 may be implicated in the pathophysiology of MDD and the combination of LRFN5 and OLFM4 may offer a diagnostic biomarker panel for MDD.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
TCF4 and RBFOX1 as peripheral biomarkers for the differential diagnosis and treatment of major depressive disorder.J Affect Disord. 2024 Jan 15;345:252-261. doi: 10.1016/j.jad.2023.10.129. Epub 2023 Oct 27. J Affect Disord. 2024. PMID: 37890537
-
Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study.J Affect Disord. 2018 Apr 15;231:74-82. doi: 10.1016/j.jad.2018.01.014. Epub 2018 Jan 31. J Affect Disord. 2018. PMID: 29454180
-
Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorder.Int Immunopharmacol. 2023 May;118:110108. doi: 10.1016/j.intimp.2023.110108. Epub 2023 Mar 31. Int Immunopharmacol. 2023. PMID: 37004349
-
Personalized medicine in major depressive disorder -- opportunities and pitfalls.Metabolism. 2013 Jan;62 Suppl 1(0 1):S34-9. doi: 10.1016/j.metabol.2012.08.021. Epub 2012 Sep 26. Metabolism. 2013. PMID: 23021040 Free PMC article. Review.
-
Emerging role of microRNAs in major depressive disorder and its implication on diagnosis and therapeutic response.J Affect Disord. 2021 May 1;286:80-86. doi: 10.1016/j.jad.2021.02.063. Epub 2021 Mar 4. J Affect Disord. 2021. PMID: 33714174 Review.
Cited by
-
A genome-wide investigation into the underlying genetic architecture of personality traits and overlap with psychopathology.Nat Hum Behav. 2024 Aug 12. doi: 10.1038/s41562-024-01951-3. Online ahead of print. Nat Hum Behav. 2024. PMID: 39134740
-
Elevated SCN11A concentrations associated with lower serum lipid levels in patients with major depressive disorder.Transl Psychiatry. 2024 May 11;14(1):202. doi: 10.1038/s41398-024-02916-w. Transl Psychiatry. 2024. PMID: 38734669 Free PMC article.
-
Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation.Mol Neurobiol. 2024 May 9. doi: 10.1007/s12035-024-04217-1. Online ahead of print. Mol Neurobiol. 2024. PMID: 38722514
-
Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans.Neuropsychopharmacology. 2024 Jun;49(7):1129-1139. doi: 10.1038/s41386-024-01811-8. Epub 2024 Feb 7. Neuropsychopharmacology. 2024. PMID: 38326457
-
A genome-wide investigation into the underlying genetic architecture of personality traits and overlap with psychopathology.medRxiv [Preprint]. 2024 Jan 17:2024.01.17.24301428. doi: 10.1101/2024.01.17.24301428. medRxiv. 2024. Update in: Nat Hum Behav. 2024 Aug 12. doi: 10.1038/s41562-024-01951-3. PMID: 38293137 Free PMC article. Updated. Preprint.
References
-
- World mental health report: transforming mental health for all. Geneva: World Health Organization; 2022.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous